Lexaria Corp., (LXRP) http://www.lexariaenergy.com/ trading on the OTCBB in the $0.16 range on a 3-Month average daily trading volume of 7,078 shares jumped out of the gate this morning from basically $0 to $0.158 (1,580%) on no official news, but on a return to trading. 

Seems the Mississippi gas and oil company supporters picked today to renew the Company's trading vitality. On June 23, 2009 changed its trading symbol from LXRA to LXRP in conjunction with a stock reverse split of 1 new share for 4 old shares. This served to reduce the number of shares issued and outstanding from the current quantity of 24,369,500 shares to a new issued and outstanding quantity of 6,092,375 shares.

Apparently the symbol change and stock restructure was based upon management's vision of a stronger company in the future: "The extraordinarily difficult market environment for financing ongoing operations, exploration and corporate expansion has convinced management that the share restructuring was necessary."

LXRP holds between 32% and 60% gross working interests in various gas and oil projects in Mississippi. Will the $0.16 hold? One will have to follow along to see.

TODAYS INTRADAY CHART OF LXRP

A TWO MONTH CHART OF LXRP

The winner in today's message board activity appears to be CPC of America (CPCF) http://www.cpcmeddevices.com/ trading on the OTCBB in the $2.50 range on an average daily trading volume of 6,225 shares with a market cap of $23 million. With no official news, the enthusiasm must be generated by the Company's June 9 announcement of its first patent filing of a synthetic sealant for its specific application to CPCF's MedClose Vascular Closure System (previously announced May 21, 2009) may represent a much broader foundation and basis for its new strategic plan as a Closure Products Company.

CPCF engages in the development, acquisition, manufacture, and distribution of cardiology medical devices, therapeutic devices, and disposable products in the U.S. CPCF products include: CPCA 2000, an external counterpulsation device for the treatment of coronary artery disease and MedClose, an internal puncture closing delivery system device that is designed to seal arterial puncture sites in patients who have undergone diagnostic or interventional catheterization procedures.

At $2.50, CPCF is below its 52-week high of $8.50 set on 07-15-08 and a dollar above its 52-week low of $1.50 set on 04-20-09. At $2.50, it is below both its 50-day and 200-day moving averages. It shares out versus float ratio is close enough to parity not to cause any concern.

ALL BOATS RISE ON A RISING TIDE

Propelling all 'stem cell' stocks higher today, the General Electric (GE) Healthcare division and Geron (private) announced an exclusive licensing agreement to develop cellular evaluation technology procured from human embryonic stem cells (hESCs). The alliance aims to assist in the discovery of new drugs, as well as the development and safety of existing ones.

That sent Opexa Therapeutics (OPXA) http://www.opexatherapeutics.com/ trading on the OTCBB in the $0.50 range past a 5% opening gain and past its 3-Month average daily trading volume of 58,956 shares. OPXA has a market cap of $6.12 million.

OPXA is a development stage biopharmaceutical company that is developing autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, and diabetics. Its therapies are based on the company's T-cell and adult stem cell technologies. On June 9, confirmed its Nasdaq listing equity requirement to regain compliance with a listing rule. Good news.

At $0.50, OPXA is well below its 52-week high of $2.74 set on 09-03-08 and far ahead of its 52-week low of $0.09 set on 11-28-08. At a half a buck, OPXA is ahead of both its 50-day and 200-day moving average and its shares out versus float ratio is stable.

BioBridge Science (BGES) http://www.bio-bridge-science.com/ trading on the OTCBB in the $1 range jumped out of the gate this morning with a 304% increase on an average daily trading volume of 90,635 shares. BGES has a market cap of $35 million.

I believe this is one of the rising boats on GE's stem cell news. On June 9, BGES entered into a joint venture with JR Scientific (private) to form a new cell culture medium enterprise in Beijing, China. The registered capital of the new joint venture will be approximately $1,464,000.

The new joint venture is expected to provide cell culture medium for scientific research and vaccine production for both internal and external purposes, as well as, to provide the Company with another source of revenue, diversified product offerings, and expanded sales and trade networks.

Bio-Bridge Science, Inc., a development stage company, engages in the commercial development of biological products for the prevention and treatment of human infectious diseases. It develops and commercializes HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV) in mainland China. The company's products under development are vaccines against HIV, cervical cancer, and colon cancer.

At one dollar, BGES is below its 52-week high of $3.50 set on 09-15-08 and far above its 52-week low of $0.22 set on 10-02-08. It is currently below both its 50-day and 200-day moving average and trailing twelve month revenues of $880 thousand. I would like to see more shares in the float than 12 million.

Finally today, one of my favorite Penny Stock companies is The Tootie Pie Company, Inc. (TOOT) http://www.tootiepieco.com/ trading on the OTCBB in the $0.13 range on an a 3-Month average daily trading volume of 2,293 shares with a market cap of $2.25 million.

I have liked TOOT for years because they are a small, solid, family-based company that makes pies. Simple as that. TOOT is the kind of company that Warren Buffet invests in (like his local furniture store in Omaha) and represents the backbone of OTCBB trading.

TOOT jumped 108% this morning on yesterday's fiscal year-end news release of its 2009 annual revenues grow 18%, its gross profit topping $1 million and its gross margins holding steady at 63%. In this recession; Tootie beat 2008's gross profits.

Don Merrill, Tootie Pie Company's President & CEO, said, "I am proud that our revenues were up and that we topped $1 million in gross profit for the first time in Company history. By focusing on the opportunities for continued growth presented by changing economic and market conditions, we have kept Tootie Pie Company well-positioned for further success.

Due to the downturn in the US economy, corporate sales did not materialize as anticipated, although we plan to aggressively work the sales leads we developed to increase corporate sales for this year. We also implemented several cost saving and expense reducing measures in response to the downturn, although the benefits achieved by these reductions were not fully recognized in the fiscal year ending March, 2009."

TOOT bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual consumers through in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of regional and national broad line foodservice distributors who purchase pies and then resell them to their customers.

At $0.13, TOOT is well below its 52-week high of $0.80 set on 09-22-08 and above its 52-week low of $0.10 set on 08-29-08. It is currently well below its 50-day and 200-day moving averages on trailing twelve month revenues of $1.65 million. It shares out versus float ratio is near-parity.

A ONE MONTH CHART FOR TOOT